Co-op Biology-Oncology Haven - CT

Arvinas is a clinical‑stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life‑threatening diseases through the discovery, development, and commercialization of therapies that degrade disease‑causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC‑targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease‑causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical‑stage programs currently enrolling: ARV‑102 for the treatment of patients with neurodegenerative disorders, ARV‑393 for the treatment of patients with relapsed/refractory non‑Hodgkin Lymphoma and potentially other lymphomas, and ARV‑806, a KRAS G12D PROTAC for the treatment of patients with solid tumors with KRAS G12D mutations.

On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant – an investigational, orally bioavailable PROTAC estrogen receptor degrader – for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1‑mutated advanced or metastatic breast cancer previously treated with endocrine‑based therapy.

In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out‑licensing and commercialization of vepdegestrant.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC‑androgen receptor protein degrader ARV‑766 for the treatment of prostate cancer. The transaction closed in May 2024.

The Spring 2026 Oncology Biology Co‑Op position at Arvinas will focus on evaluating the effect of novel heterobifunctional degrader molecules on intracellular oncology targets and on validating newly proposed targets for potential degrader discovery efforts. This position will involve cell biology and molecular biology techniques, and potentially new target proposition workflows. The candidate will join a collaborative, multi‑disciplinary team of biologists, biochemists, biophysicists, and chemists.

This is a laboratory‑based role dedicated to validating novel oncology targets through functional and mechanistic studies, including the design and execution of in‑vitro cellular assays to establish the biological rationale for PROTAC‑based therapeutic approaches. We are looking for a passionate and highly motivated individual who is enthusiastic about novel therapeutic applications, such as degraders, and wants to contribute to exploring new targets for degradation in the oncology space.

This training opportunity allows the individual to learn the process of early drug discovery in a collaborative environment.

This position reports to a Senior Research Investigator, Biology, Oncology and will be located at our headquarters in New Haven, CT.

• Cell culture including sterile technique for mammalian cell lines
• Functional genomics approaches (such as CRISPR KO, siRNA/shRNA KD) to interrogate targets to understand their biological function, especially at scale or in a hypothesis‑driven way
• Cellular assays to monitor activity of degrader compounds (such as Western blot, JESS, high‑content imaging, HiBiT, NanoBRET)
• Establishing and developing new assays to detect target engagement and small molecule binding to targets in vitro and in cells
• Data analysis and interpretation, as well as presenting data in team meetings.
• Meeting with key stakeholders outside of the project team to devise future experiments for downstream applications

• The candidate should be a highly motivated fast learner with flexibility and ability to multi‑task, as well as a good lab citizen.
• Experience in cell culture is required.
• Experience with immunoblotting and genetic perturbation assay skills are…